Founded in 2002 and based in Seattle, LabConnect manages central lab testing through a global network of primary and specialty laboratories rather than owning its own labs. The company focuses on logistics, project management, data management, reporting, kit building, sample management, biorepository services, and scientific support. LabConnect serves small and mid-tier biopharmaceutical customers and accommodates projects of varying size, complexity, and geography across many therapeutic areas. The firm emphasizes its technology platform to enable seamless integration between customers and laboratory partners and superior project and data management. Management cites increased R&D spending and a trend toward outsourcing clinical trial work as a significant market opportunity. The company plans to use new funding to enhance its technology platform, expand products and services, and grow its sales team. LabConnect is a provider of global central laboratory services and comprehensive support for biopharmaceutical, medical device and contract research organizations. Its services include routine and esoteric laboratory testing, clinical kit building, sample tracking and management (SampleGISTICS), biorepository and scientific operations support, plus sample preparation services such as RNA/DNA extraction, PBMC processing and blood fractionation. The company reports a compound annual growth rate of nearly 40 percent over the last several years and is pursuing an internal "2020 Vision" to drive further expansion. To support growth it recently added a 42,000-square-foot operations center in Johnson City, Tenn., with state-of-the-art sample management, biorepository capabilities and kit-building space. The company was founded in 2002 and is announced from Seattle. LabConnect positions itself as a single-provider solution combining technology, laboratory capacity and specialized testing expertise for drug development clients.

Total raised

$29M

Funding rounds

2

Latest round

Series A

Latest activity

Jun 2017